13 November 2017: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, intends to announce its interim results for the six months ended 30 September 2017 on Thursday 14 December 2017.
Data Safety Monitoring Board gives approval for ongoing retinitis pigmentosa clinical trial to progress into Phase II element based on short term safety data
8 November 2017: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today provides an update regarding the Company’s ongoing Phase I/II clinical trial of its hRPC cell therapy candidate for the blindness-causing disease, retinitis pigmentosa (“RP”).
Long term data from Phase II stroke clinical trial confirm positive results seen after three months.
Results indicate that CTX cell therapy has potential to improve long term outcomes in disability, dependence and motor function in disabled stroke patients.
31 October 2017: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today provides an update regarding the Company’s Phase II clinical trial (PISCES II) of its CTX cell therapy candidate for stroke disability and, in addition, an update regarding its global clinical and regulatory development strategy for the stroke programme.
27 October 2017: ReNeuron Group plc (the “Company”) (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it is the lead industry participant in a new grant award from the Welsh Government to advance its emerging exosome therapy platform.
11 October 2017: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, presents positive pre-clinical data with its ExoPr0 exosome cancer therapy candidate at major scientific conference.
6 September 2017: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that all resolutions put to shareholders at today’s Annual General Meeting were duly passed.
6th September 2017: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to provide a trading update ahead of today’s Annual General Meeting.
To see the slides accompanying the presentation made at the AGM please click here.
1 September 2017: ReNeuron Group plc (the “Company”) (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce the appointment of Dr Claudia D’Augusta as a Non-executive Director of the Company, effective from the date of the Company’s Annual General Meeting on 6 September 2017. She will also chair the Company’s Audit Committee.
01 September 2017: ReNeuron Group plc (the “Company”) (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements.
7 August 2017: ReNeuron Group plc (“the Company”) (AIM: RENE), a leading UK-based stem cell therapy development company, announces that its Annual Report and Accounts for the year ended 31 March 2017 and the Notice of the 2017 Annual General Meeting (“AGM”) have been sent to shareholders and are also available on the Company’s website at www.reneuron.com.
The Annual Report and Accounts can be found under the Investors section or by clicking here.
For our archived news, click here
